CompletedPhase 2NCT00743509

A Phase II Study of Oral Cyclophosphamide and Sirolimus (OCR) in Advanced Sarcoma

Studying Osteosarcoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
University of Michigan Rogel Cancer Center
Principal Investigator
Scott Schuetze, MD, PhD
University of Michigan Rogel Cancer Center
Intervention
Cyclophosphamide and Sirolimus(drug)
Enrollment
49 enrolled
Eligibility
16 years · All sexes
Timeline
20082012

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00743509 on ClinicalTrials.gov

Other trials for Osteosarcoma

Additional recruiting or active studies for the same condition.

See all trials for Osteosarcoma

← Back to all trials